ethyl 3-aminobutyl(diethoxymethyl)phosphinate | 103680-65-5

• 分子结构分类: 有机化合物 - 有机磷化合物 - 有机膦酸及其衍生物
• 英文名称: ethyl 3-aminobutyl(diethoxymethyl)phosphinate
• 英文别名: Ethyl (3-aminobutyl)(diethoxymethyl)phosphinate；4-[diethoxymethyl(ethoxy)phosphoryl]butan-2-amine
• CAS: 103680-65-5
• 化学式: C₁₁H₂₆NO₄P
• 分子量: 267.305
• InChiKey: ZVUYFMOSURHPHS-UHFFFAOYSA-N

物化性质

• 沸点：
  150 °C(Press: 0.01 Torr)
• 密度：
  1.036±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  0.3
• 重原子数：
  17
• 可旋转键数：
  10
• 环数：
  0.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  70.8
• 氢给体数：
  1
• 氢受体数：
  5

反应信息

• 作为反应物：
  描述：

  ethyl 3-aminobutyl(diethoxymethyl)phosphinate 在 盐酸 、 methyloxirane 作用下， 生成 3-aminobutylphosphonous acid
  参考文献：
  名称：

  Diethoxymethylphosphonites and phosphinates. Intermediates for thesynthesis of α,β- and X aminoalkylphosphonous acids

  摘要：

  DOI：

  10.1016/s0040-4020(01)89240-1
• 作为产物：
  描述：

  (乙氧基)[双(乙氧基)甲基](三甲基硅氧基)膦 在 ammonium acetate 、 水 、 sodium cyanoborohydride 作用下， 反应 1.5h， 生成 ethyl 3-aminobutyl(diethoxymethyl)phosphinate
  参考文献：
  名称：

  Diethoxymethylphosphonites and phosphinates. Intermediates for thesynthesis of α,β- and X aminoalkylphosphonous acids

  摘要：

  DOI：

  10.1016/s0040-4020(01)89240-1

文献信息

• Substituted propane-phosphinic acid compounds
  申请人：Ciba-Geigy Corporation

  公开号：US05064819A1

  公开（公告）日：1991-11-12

  Compounds of the formula I ##STR1## wherein R denotes an aliphatic, cycloaliphatic, cycloaliphatic-aliphatic or araliphatic radical having 2 or more carbon atoms, and wherein one of the groups R.sup.1, R.sup.2 and R.sup.3 represents hydrogen or an aliphatic, cycloaliphatic, araliphatic or aromatic radical, another one of R.sup.1, R.sup.2 and R.sup.3 is hydrogen or, in the case of R.sup.1 and R.sup.2, is hydroxy, and the remaining one of R.sup.1, R.sup.2 and R.sup.3 is hydrogen, or wherein R denotes methyl, R.sub.1 denotes hydrogen or hydroxy, R.sub.2 denotes an aromatic radical and R.sub.3 represents hydrogen, and their salts have GABA.sub.B -antagonistic properties and can be used as GABA.sub.B -antagonists. They are obtained when in a compound of formula II ##STR2## in which R, R.sup.1, R.sup.2 and R.sup.3 have their previous significances, Z represents --NH.sub.2 and R.sup.4 denotes a hydroxy-protective group R.sup.5 or, when R.sup.1 and R.sup.3 denote hydrogen and R.sup.2 denotes hydrogen or alkyl, denotes an alkali metal or ammonium ion R.sup.6, or Z represents a protected or latent amino group Z.sup.0 and R.sup.4 denotes hydrogen or a hydroxy-protective group R.sup.5, any group R.sup.5 or R.sup.6 is replaced by hydrogen, and/or any group Z.sup.0 is converted into --NH.sub.2.

  公式I的化合物##STR1##其中R表示具有2个或更多碳原子的脂肪族、环脂族、环脂族-脂肪族或芳基脂肪基，其中R.sup.1、R.sup.2和R.sup.3中的一个代表氢或脂肪族、环脂族、芳基脂肪基或芳香族基，R.sup.1、R.sup.2和R.sup.3中的另一个是氢或在R.sup.1和R.sup.2的情况下是羟基，而R.sup.1、R.sup.2和R.sup.3中的剩余一个是氢，或者R表示甲基，R.sub.1表示氢或羟基，R.sub.2表示芳基，R.sub.3表示氢，它们的盐具有GABA.sub.B-拮抗性质，可用作GABA.sub.B-拮抗剂。当在公式II的化合物中获得它们##STR2##其中R、R.sup.1、R.sup.2和R.sup.3具有其先前的含义，Z表示--NH.sub.2，R.sup.4表示羟基保护基R.sup.5或者当R.sup.1和R.sup.3表示氢且R.sup.2表示氢或烷基时，表示碱金属或铵离子R.sup.6，或者Z表示受保护或潜在的氨基Z.sup.0且R.sup.4表示氢或羟基保护基R.sup.5，任何一个R.sup.5或R.sup.6基团被氢取代，和/或任何一个Z.sup.0基团被转化为--NH.sub.2。
• Substituted propane-phosphonous acid compounds
  申请人：Ciba-Geigy Corporation

  公开号：US04656298A1

  公开（公告）日：1987-04-07

  The compounds of the formula ##STR1## in which one of the groups R.sup.1, R.sup.2 and R.sup.3 represents hydrogen, C.sub.1-8 -alkyl, C.sub.3-6 -cycloalkyl, phenyl optionally substituted by halogeno, C.sub.1-4 -alkyl, C.sub.1-4 -alkoxy and/or trifluoromethyl, or C.sub.7-10 -phenylalkyl optionally substituted in the phenyl moiety by halogeno, C.sub.1-4 -alkyl, C.sub.1-4 -alkoxy and/or trifluormethyl, and the other two are hydrogen, or salts thereof. These compounds have valuable pharmaceutical properties.

  公式##STR1##中的化合物，其中R.sup.1、R.sup.2和R.sup.3中的一个代表氢、C.sub.1-8-烷基、C.sub.3-6-环烷基、苯基（可选择地被卤素取代）、C.sub.1-4-烷基、C.sub.1-4-烷氧基和/或三氟甲基，或C.sub.7-10-苯基烷基，苯基部分可选择地被卤素、C.sub.1-4-烷基、C.sub.1-4-烷氧基和/或三氟甲基取代，另外两个是氢，或其盐。这些化合物具有宝贵的药用性能。
• Substituted propane-phosponous acid compounds
  申请人：Ciba-Geigy Corporation

  公开号：US05457095A1

  公开（公告）日：1995-10-10

  The compounds of the formula ##STR1## in which one of the groups R.sup.1, R.sup.2 and R.sup.3 represents hydrogen, C.sub.1-8 -alkyl, C.sub.3-6 -cycloalkyl, phenyl optionally substituted by halogeno, C.sub.1-4 -alkyl, C.sub.1-4 -alkoxy and/or trifluoromethyl, or C.sub.7-10 -phenylalkyl optionally substituted in the phenyl moiety by halogeno, C.sub.1-4 -alkyl, C.sub.1-4 -alkoxy and/or trifluormethyl, and the other two are hydrogen, or salts thereof. These compounds have valuable pharmaceutical properties.

  式子为 ##STR1## 的化合物，其中R.sup.1、R.sup.2和R.sup.3中的一个代表氢、C.sub.1-8-烷基、C.sub.3-6-环烷基、苯基，该苯基可选择地被卤素、C.sub.1-4-烷基、C.sub.1-4-烷氧基和/或三氟甲基取代，或C.sub.7-10-苯基烷基，该苯基烷基可选择地被卤素、C.sub.1-4-烷基、C.sub.1-4-烷氧基和/或三氟甲基取代，另外两个为氢，或其盐。这些化合物具有有价值的药物性质。
• Substituted propane-phosphonuous acid compounds
  申请人：Ciba-Geigy Corporation

  公开号：US04772738A1

  公开（公告）日：1988-09-20

  The compounds of the formula ##STR1## in which one of the groups R.sup.1, R.sup.2 and R.sup.3 represents hydrogen, C.sub.1-8 -alkyl, C.sub.3-6 -cycloalkyl, phenyl optionally substituted by halogeno, C.sub.1-4 -alkyl, C.sub.1-4 -alkoxy and/or trifluoromethyl, or C.sub.7-10 -phenylalkyl optionally substituted in the phenyl moiety by halogeno, C.sub.1-4 -alkyl, C.sub.1-4 -alkoxy and/or trifluormethyl, and the other two are hydrogen, or salts thereof. These compounds have valuable pharmaceutical properties.

  式子为##STR1##的化合物，其中R.sup.1、R.sup.2和R.sup.3中的一个代表氢，C.sub.1-8-烷基，C.sub.3-6-环烷基，苯基，该苯基可选用卤代基，C.sub.1-4-烷基，C.sub.1-4-烷氧基和/或三氟甲基，或C.sub.7-10-苯基烷基，该苯基烷基中的苯基可选用卤代基，C.sub.1-4-烷基，C.sub.1-4-烷氧基和/或三氟甲基，而另外两个是氢，或其盐。这些化合物具有有价值的药物特性。
• Novel substituted propane phosphinic acid compounds
  申请人：CIBA-GEIGY AG

  公开号：EP0319482A2

  公开（公告）日：1989-06-07

  Compounds of the formula I wherein R denotes an aliphatic, cycloaliphatic, cycloaliphatic-aliphatic or araliphatic radical having 2 or more carbon atoms, and wherein one of the groups R¹, R² and R³ represents hydrogen or an aliphatic, cyclo­aliphatic, araliphatic or aromatic radical, another one of R¹, R² and R³ is hydrogen or, in the case of R¹ and R², is hydroxy, and the remaining one of R¹, R² and R³ is hydrogen, and their salts have GABAB-anta­gonistic properties and can be used as GABAB-antagonists. They are obtained when in a compound of formula II in which R, R¹, R² and R³ have their previous significances, Z represents -NH₂ and R⁴ denotes a hydroxy-protective group R⁵ or, when R¹ and R³ denote hydrogen and R² denotes hydrogen or alkyl, denotes an alkali metal or ammonium ion R⁶, or Z represents a protected or latent amino group Zo and R⁴ denotes hydrogen or a hydroxy-protective group R⁵, any group R⁵ or R⁶ is replaced by hydrogen, and/or any group Zo is converted into -NH₂.

  式 I 的化合物 其中 R 表示具有 2 个或 2 个以上碳原子的脂肪族、环脂族、环脂族-脂肪族或芳香族基团，其中基团 R¹、R² 和 R³ 中的一个代表氢或脂肪族、环脂族、芳香族或芳香族基团、R¹、R² 和 R³ 中的另一个为氢，或在 R¹ 和 R² 的情况下为羟基，R¹、R² 和 R³ 中的其余一个为氢，它们的盐具有 GABAB 拮抗特性，可用作 GABAB 拮抗剂。当式 II 的化合物中 其中 R、R¹、R² 和 R³ 具有其先前的意义，Z 表示-NH₂，R⁴ 表示羟基保护基团 R⁵，或当 R¹ 和 R³ 表示氢，R² 表示氢或烷基时，表示碱金属或铵离子 R⁶、或 Z 代表受保护或潜在的氨基 Zo，R⁴ 表示氢或羟基保护基团 R⁵，任何基团 R⁵ 或 R⁶ 被氢取代，和/或任何基团 Zo 转化为-NH₂。